Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Human Acid Sphingomyelinase Deficiency: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Human Acid Sphingomyelinase Deficiency: 1 US clinical trial tracked, none currently recruiting.

Human Acid Sphingomyelinase Deficiency is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Genzyme, a Sanofi Company, running 1 of these trials.

Enrollment posture brief

Registry condition human-acid-sphingomyelinase-deficiency

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Human Acid Sphingomyelin (th…0%
Open-enrollment share among volume-matched conditions near Human Acid Sphingomyelinase Deficiency

Human Acid Sphingomyelinase Deficiency has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Human Acid Sphingomyelinase Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Human Acid Sphingomyelinase Deficiency is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Human Acid Sphingomyelinase Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Recombinant human acid sphingomyelinase Drug
1 trials

US sites by state

Facility locations filed on Human Acid Sphingomyelinase Deficiency trials. A trial with sites in several states counts in each.

New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Human Acid Sphingomyelinase Deficiency page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Human Acid Sphingomyelinase Deficiency trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Genzyme, a Sanofi Company sponsors the most Human Acid Sphingomyelinase Deficiency trials on record, review their full trial history before evaluating a specific study. See Genzyme, a Sanofi Company's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Acid Sphingomyelinase Deficiency condition card totals 1 registered trials; most-linked intervention Recombinant human acid sphingomyelinase; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.